Literature DB >> 15322656

Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction.

Aline Ranzolin1, Jussara Marilú Bohn, Gary L Norman, Euler Manenti, Luis Carlos Bodanese, Carlos Alberto von Mühlen, Henrique Luiz Staub.   

Abstract

OBJECTIVE: To determine whether high levels of antibodies against the phospholipid beta2-glycoprotein I (beta2-gpI) cofactor are associated with an increase in the risk of acute myocardial infarction.
METHODS: The study comprised 82 patients with acute myocardial infarction and 82 controls, who were assessed in regard to age, sex, race, hypertension, smoking, previous heart disease, history of diabetes mellitus, and hypercholesterolemia. The following antibodies were detected using immunoassay: anticardiolipin and anti-beta2-gpI IgA, IgG, and IgM. Adjusted odds ratios (OR) for risk factors were obtained through logistic regression.
RESULTS: The mean ages of the cases and controls were, respectively, 57.7 and 51.1 years (P=0.003). Men (P=0.005) and the white race predominated in both groups (P=0.798). Of the risk factors, a history of diabetes (OR=5.3; 95% CI: 1.9 to 14.9; P=0.001) and previous heart disease (OR=4.7; 95% CI: 2.0 to 10.7; P<0.001) were the most consistent associations with myocardial infarction. The frequency of anticardiolipin IgG, IgM, and IgA antibodies did not differ between cases and controls (P=1.000). Anti-beta2-gpI IgA antibodies were more frequent in cases than in controls (P=0.054). The adjusted OR for anti-beta2-gpI IgA antibodies was 3.4 (95% CI: 1.3 to 9.1; P=0.015).
CONCLUSION: Anti-beta2-gpI IgA antibodies, but not anticardiolipin antibodies, seemed to behave as independent risk factors for myocardial infarction, which may represent a link between autoimmunity and atherosclerosis in patients with acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322656     DOI: 10.1590/s0066-782x2004001400005

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  9 in total

Review 1.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

2.  Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Authors:  Vijaya Murthy; Rohan Willis; Zurina Romay-Penabad; Patricia Ruiz-Limón; Laura A Martínez-Martínez; Shraddha Jatwani; Praveen Jajoria; Alan Seif; Graciela S Alarcón; Elizabeth Papalardo; Jigna Liu; Luis M Vilá; Gerald McGwin; Terry A McNearney; Rashmi Maganti; Prashanth Sunkureddi; Trisha Parekh; Michael Tarantino; Ehtisham Akhter; Hong Fang; Emilio B Gonzalez; Walter R Binder; Gary L Norman; Zakera Shums; Marius Teodorescu; John D Reveille; Michelle Petri; Silvia S Pierangeli
Journal:  Arthritis Rheum       Date:  2013-12

3.  Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions.

Authors:  Jison Hong; David J Maron; Tsuyoshi Shirai; Cornelia M Weyand
Journal:  Int J Clin Rheumtol       Date:  2015-10

Review 4.  The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome.

Authors:  Oscar Cabrera-Marante; Edgard Rodríguez de Frías; Manuel Serrano; Fernando Lozano Morillo; Laura Naranjo; Francisco J Gil-Etayo; Estela Paz-Artal; Daniel E Pleguezuelo; Antonio Serrano
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

Review 5.  VWF, Platelets and the Antiphospholipid Syndrome.

Authors:  Shengshi Huang; Marisa Ninivaggi; Walid Chayoua; Bas de Laat
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

6.  Sericin-mediated improvement of dysmorphic cardiac mitochondria from hypercholesterolaemia is associated with maintaining mitochondrial dynamics, energy production, and mitochondrial structure.

Authors:  Kitiya Rujimongkon; Sumate Ampawong; Duangnate Isarangkul; Onrapak Reamtong; Pornanong Aramwit
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

7.  The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study.

Authors:  Faruk Ertaș; Oznur Can; Halit Acet; Mert Ozbakkaloglu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-11-18       Impact factor: 1.426

8.  Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry's disease.

Authors:  A Nandagudi; E C Jury; D Alonzi; T D Butters; S Hughes; D A Isenberg
Journal:  Lupus       Date:  2013-07-17       Impact factor: 2.911

9.  Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.

Authors:  Meng Xiao; Yan Zhang; Shulan Zhang; Xuzhen Qin; Peng Xia; Wei Cao; Wei Jiang; Huan Chen; Xin Ding; Hua Zhao; Hongmin Zhang; Chunyao Wang; Jing Zhao; Xuefeng Sun; Ran Tian; Wei Wu; Dong Wu; Jie Ma; Yu Chen; Dong Zhang; Jing Xie; Xiaowei Yan; Xiang Zhou; Zhengyin Liu; Jinglan Wang; Bin Du; Yan Qin; Peng Gao; Minya Lu; Xin Hou; Xian Wu; Huadong Zhu; Yingchun Xu; Wen Zhang; Taisheng Li; Fengchun Zhang; Yongqiang Zhao; Yongzhe Li; Shuyang Zhang
Journal:  Arthritis Rheumatol       Date:  2020-10-07       Impact factor: 15.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.